🚀 VC round data is live in beta, check it out!
TTY Biopharm Valuation Multiples
Discover revenue and EBITDA valuation multiples for TTY Biopharm and similar public comparables like Prothena Corp., Luzhu Biotech, Cormedix, Verastem and more.
TTY Biopharm Overview
About TTY Biopharm
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
Founded
1960
HQ
Employees
561
Website
Sectors
Financials (LTM)
EV
$532M
TTY Biopharm Financials
TTY Biopharm reported last 12-month revenue of $209M.
In the same LTM period, TTY Biopharm generated $50M in net income.
Revenue (LTM)
TTY Biopharm P&L
In the most recent fiscal year, TTY Biopharm reported revenue of $204M and EBITDA of $75M.
TTY Biopharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $209M | XXX | $204M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $118M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 58% | XXX | XXX | XXX |
| EBITDA | — | XXX | $75M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 37% | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| Net Profit | $50M | XXX | $49M | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 24% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
TTY Biopharm Stock Performance
TTY Biopharm has current market cap of $588M, and enterprise value of $532M.
Market Cap Evolution
TTY Biopharm's stock price is $2.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $532M | $588M | 0.6% | XXX | XXX | XXX | $0.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTTY Biopharm Valuation Multiples
TTY Biopharm trades at 2.6x EV/Revenue multiple, and 7.1x EV/EBITDA.
EV / Revenue (LTM)
TTY Biopharm Financial Valuation Multiples
As of April 18, 2026, TTY Biopharm has market cap of $588M and EV of $532M.
Equity research analysts estimate TTY Biopharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TTY Biopharm has a P/E ratio of 11.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $588M | XXX | $588M | XXX | XXX | XXX |
| EV (current) | $532M | XXX | $532M | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBIT | 9.3x | XXX | 9.8x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.5x | XXX | XXX | XXX |
| P/E | 11.7x | XXX | 11.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 10.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TTY Biopharm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
TTY Biopharm Margins & Growth Rates
TTY Biopharm's revenue in the last 12 month grew by 7%.
TTY Biopharm's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
TTY Biopharm Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 11% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
TTY Biopharm Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| TTY Biopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Prothena Corp. | XXX | XXX | XXX | XXX | XXX | XXX |
| Luzhu Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Cormedix | XXX | XXX | XXX | XXX | XXX | XXX |
| Verastem | XXX | XXX | XXX | XXX | XXX | XXX |
| Rigel Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TTY Biopharm M&A Activity
TTY Biopharm acquired XXX companies to date.
Last acquisition by TTY Biopharm was on XXXXXXXX, XXXXX. TTY Biopharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by TTY Biopharm
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTTY Biopharm Investment Activity
TTY Biopharm invested in XXX companies to date.
TTY Biopharm made its latest investment on XXXXXXXX, XXXXX. TTY Biopharm invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by TTY Biopharm
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TTY Biopharm
| When was TTY Biopharm founded? | TTY Biopharm was founded in 1960. |
| Where is TTY Biopharm headquartered? | TTY Biopharm is headquartered in Taiwan. |
| How many employees does TTY Biopharm have? | As of today, TTY Biopharm has over 561 employees. |
| Is TTY Biopharm publicly listed? | Yes, TTY Biopharm is a public company listed on Taipei Exchange. |
| What is the stock symbol of TTY Biopharm? | TTY Biopharm trades under 4105 ticker. |
| When did TTY Biopharm go public? | TTY Biopharm went public in 2001. |
| Who are competitors of TTY Biopharm? | TTY Biopharm main competitors are Prothena Corp., Luzhu Biotech, Cormedix, Verastem. |
| What is the current market cap of TTY Biopharm? | TTY Biopharm's current market cap is $588M. |
| What is the current revenue of TTY Biopharm? | TTY Biopharm's last 12 months revenue is $209M. |
| What is the current revenue growth of TTY Biopharm? | TTY Biopharm revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of TTY Biopharm? | Current revenue multiple of TTY Biopharm is 2.6x. |
| Is TTY Biopharm profitable? | Yes, TTY Biopharm is net-income-positive (as of the last 12 months). |
| What is the current net income of TTY Biopharm? | TTY Biopharm's last 12 months net income is $50M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.